SC
LCTX icon

SummitTX Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

SummitTX Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.1K Buy
60,833
+39,514
+185% +$66.6K ﹤0.01% 715
2025
Q4 		$35.6K Sell
21,319
-52,516
-71% -$90.9K ﹤0.01% 671
2025
Q3 		$125K Sell
73,835
-212,685
-74% -$252K 0.01% 715
2025
Q2 		$260K Buy
+286,520
New +$170K 0.01% 645

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SummitTX Capital's LCTX Position: Q1 2026 in Review

SummitTX Capital increased its Lineage Cell Therapeutics (LCTX) stake by 185% in Q1 2026, buying an estimated $66.6K and bringing the position to 60,833 shares worth $96.1K. The position accounts for ﹤0.01% of the portfolio, ranked #715.

SummitTX Capital first reported a position in LCTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $260K in Q2 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • SummitTX Capital held 60,833 shares of Lineage Cell Therapeutics worth $96.1K as of Q1 2026.
  • SummitTX Capital bought 39,514 Lineage Cell Therapeutics shares in Q1 2026, an estimated $66.6K.
  • Lineage Cell Therapeutics made up ﹤0.01% of SummitTX Capital's portfolio in Q1 2026, its #715 holding.
  • SummitTX Capital first reported a position in Lineage Cell Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • SummitTX Capital's Lineage Cell Therapeutics position peaked at $260K in Q2 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.